How do you know that something to do with heart failure was due Q3 2022 - also, you do know that delivery date was either in the March quarter of FY22 or the September quarter of CY22, either way it is past tense - or that mitral regurgitation is in "Q2 2023"? Genuine question as I do seem to struggle unravelling some of their announcements and updates. I saw mention of those conditions in one of the announcements but nothing about the timing.
Just to be pedantic companies don't get a FDA "approval" with a 510(k) process, but rather a "clearance". Apparently there is a difference.
Ann: Echo IQ Announces Positive Results From US Clinical Study, page-13
Add EIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $132.4M | |||
| Open | High | Low | Value | Volume |
| 22.5¢ | 22.8¢ | 22.5¢ | $20.51K | 91.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 345351 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 171248 | 5 |
View Market Depth
| Last trade - 10.31am 01/10/2024 (20 minute delay) ? |
| EIQ (ASX) Chart |